Epigenetic Alteration in Colorectal Cancer: A Biomarker for Diagnostic and Therapeutic Application

Abstract

Colorectal cancer (CRC) is the leading cause of cancer death worldwide. A crucial process that initiates and progresses CRC is various epigenetic and genetic changes occurring in colon epithelial cells. Recently, huge progress has been made to understand cancer epigenetics, especially regarding DNA methylation changes, histone modifications, dysregulation of miRNAs and noncoding RNAs. In the “epigenome” of colon cancer, abnormal methylation of genes that cause gene alterations or expression of miRNA has been reported in nearly all CRC; these findings can be encountered in the average CRC methylome. Epigenetic changes, known as driving events, are assumed to play a dominant part in CRC. Furthermore, as epigenetic changes in CRC become properly understood, these changes are being established as clinical biomarkers for therapeutic and diagnostic purposes. Progression in this area indicates that epigenetic changes will often be utilized in the future to prevent and treat CRC.

Keywords

colorectal cancer / DNA methylation / epigenetics

References

[1] Pancione M, Remo A, Colantuoni V.Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int 2012; 2012: 509348

[2] Stoffel EM, Boland CR. Genetics and genetic testing in hereditary colorectal cancer. Gastroenterology2015; 149 (05): 1191-1203.e2

[3] Naghibalhossaini F, Zamani M, Mokarram P, Khalili I, Rasti M, Mostafavi-Pour Z.Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran. Mol Biol Rep 2012; 39(05): 6171-6178

[4] Zamani M, Hosseini SV, Mokarram P.Epigenetic biomarkers in colorectal cancer: premises and prospects. Biomarkers 2018; 23(02): 105-114

[5] Mokarram P, Kavousipour S, Sarabi MM.et al.MGMT-B gene promoter hypermethylation in patients with inflammatory bowel disease - a novel finding. Asian Pac J Cancer Prev 2015; 16(05): 1945-1952

[6] Schnekenburger M, Diederich M.Epigenetics offer new horizons for colorectal cancer prevention. Curr Colorectal Cancer Rep 2012; 8(01): 66-81

[7] Dunn BK.Hypomethylation: one side of a larger picture. Ann N Y Acad Sci 2003; 983(01): 28-42

[8] Hur K, Cejas P, Feliu J.et al.Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut 2014; 63(04): 635-646

[9] Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JPJ.CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96(15): 8681-8686

[10] Nazemalhosseini Mojarad E, Kuppen PJK, Aghdaei HA, Zali MR.The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench 2013; 6(03): 120-128

[11] Mokarram P, Zamani M, Kavousipour S.et al.Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer. Mol Biol Rep 2013; 40(05): 3851-3857

[12] Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology2015; 149 (05): 1204-1225.e12

[13] Naini MA, Mokarram P, Kavousipour S.et al.Sensitive and noninvasive detection of aberrant SFRP2 and MGMT-B methylation in Iranian patients with colon polyps. Asian Pac J Cancer Prev 2016; 17(04): 2185-2193

[14] Mokarram P, Shakiba-Jam F, Kavousipour S, Sarabi MM, Seghatoleslam A.Promoter methylation status of two novel human genes, UBE2Q1 and UBE2Q2, in colorectal cancer: a new finding in Iranian patients. Asian Pac J Cancer Prev 2015; 16(18): 8247-8252

[15] Shapiro B, Chakrabarty M, Cohn EM, Leon SA.Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983; 51(11): 2116-2120

[16] Ng JMK, Yu J.Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci 2015; 16(02): 2472-2496

[17] Alonso S, González B, Ruiz-Larroya T.et al.Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer. Clin Epigenetics 2015; 7(01): 124

[18] Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9(08): 2898-2903

[19] Min BH, Bae JM, Lee EJ.et al.The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011; 11(01): 344

[20] Jover R, Nguyen T-P, Pérez-Carbonell L.et al.5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. AIDS Behav 2012; 23(01): 1031-1043

[21] Meng WJ, Yang L, Ma Q.et al.MicroRNA expression profile reveals miR-17-92 and miR-143-145 cluster in synchronous colorectal cancer. Medicine (Baltimore) 2015; 94(32): e1297

[22] Baylin SB, Jones PA.A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011; 11(10): 726-734

[23] Fraga MF, Ballestar E, Villar-Garea A.et al.Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37(04): 391-400

[24] Tamagawa H, Oshima T, Shiozawa M.et al.The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep 2012; 27(03): 637-642

[25] Gezer U, Üstek D, Yörüker EE.et al.Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumour Biol 2013; 34(01): 329-336

[26] Lee S, Kim G, Kim H.et al.Lee et al. Reply. Phys Rev Lett 2007; 99(17): 179704

[27] Vasudevan S, Tong Y, Steitz JA.Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318(5858): 1931-1934

[28] Coppedè F.The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol 2014; 8(08): 935-948

[29] Bonfrate L, Altomare DF, Di Lena M.et al.MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. J Gastrointestin Liver Dis 2013; 22(03): 311-320

[30] Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH.MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J Transl Med 2012; 10(01): 128

[31] Schetter AJ, Leung SY, Sohn JJ.et al.MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299(04): 425-436

[32] Toiyama Y, Takahashi M, Hur K.et al.Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013; 105(12): 849-859

[33] Basati G, Razavi AE, Pakzad I, Malayeri FA.Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumour Biol 2016; 37(02): 1781-1788

[34] Peng J, Xie Z, Cheng L.et al.Paired design study by real-time PCR: miR-378* and miR-145 are potent early diagnostic biomarkers of human colorectal cancer. BMC Cancer 2015; 15(01): 158

RIGHTS & PERMISSIONS

2022 Global Medical Genetics